Venous thromboembolism, consisting of deep vein thrombosis (DVT) and pulmonary emboli (PE), is a significant health concern affecting hundreds of thousands of Americans each year. This condition causes substantial morbidity and mortality and is one of the most common reasons patients are referred to hematologists.

In adults, DVT/PE has an incidence of 2 to 3 per 1000 person-years. Between 300,000 to 600,000 people in the United States develop DVT/PE annually, causing at least 60,000 to 100,000 deaths each year.

Urgent treatment of DVT and PE with anticoagulation reduces mortality and morbidity, prevents clot extension, and decreases the risk of recurrence. PEs can cause strain on the right ventricle, potentially leading to left ventricular strain and cardiovascular collapse. Deep vein thrombi can migrate toward the heart, particularly proximal DVTs in the popliteal vein and above.

Clot-busting therapy is considered when there's hemodynamic compromise or when DVT is so extensive it affects venous outflow, potentially causing phlegmasia cerulea dolens—a compartment-syndrome-like condition.

Thrombophilias are inherited or acquired conditions that increase the risk of blood clot formation. Let's explore the major types:

Factor V is a clotting factor produced by the liver that helps stabilize fibrin clots. Factor V Leiden is a genetic variant where a point mutation renders the factor more resistant to degradation by activated protein C. It's also known as activated protein C resistance, named after the Dutch city where it was discovered.

Prothrombin (Factor II) is a clotting factor that converts to thrombin during the clotting cascade. The prothrombin gene mutation is a single nucleotide change (G to A) at position 20210, leading to elevated prothrombin levels and increased clot formation risk.

Antithrombin (antithrombin III) is a natural anticoagulant protein that inhibits several clotting factors, most importantly thrombin and Factor Xa. It's one of the body's natural "brakes" on the clotting system. Heparin works by enhancing antithrombin's activity.

The significantly elevated VTE risk warrants more aggressive prevention and treatment compared to Factor V Leiden or prothrombin gene mutation.

Protein C and Protein S are natural anticoagulants produced by the liver that work together as the "brakes" on the clotting system. Protein S acts as a cofactor (helper) for activated protein C, enhancing its ability to break down activated clotting factors.

Both inherited in autosomal dominant pattern—only need one abnormal gene. About 50% of people with hereditary protein S deficiency will experience a clot by age 45 without preventive measures.

Can vary from no symptoms to life-threatening complications:

Common Presentations:

Severe Protein C Deficiency - Neonatal Purpura Fulminans: Rare but life-threatening condition in newborns with extremely low or absent protein C (homozygous deficiency), presenting within hours to days after birth with widespread blood clots in small vessels and purple skin lesions. Requires immediate treatment with protein C concentrate.

Warfarin-Induced Skin Necrosis: When starting warfarin in someone with severe protein C deficiency, the drug initially drops protein C levels faster than clotting factors, creating temporary hypercoagulable state. Can cause painful skin necrosis within 3-5 days of starting warfarin. This is why heparin must be given first.

When to Test:

Tests:

Critical Timing: Do NOT test during:

Wait at least 2-4 weeks after stopping anticoagulation and after acute illness resolves. Repeat testing recommended to confirm diagnosis.

No Prior Clot: Usually no medication needed. Focus on avoiding risk factors:

After a Clot:

Special Situations:

Generally good with proper management:

Understanding venous thromboembolism and thrombophilias is essential for prevention and management:

✓ VTE is a significant health concern affecting hundreds of thousands annually
✓ Urgent anticoagulation treatment is critical for reducing mortality and morbidity
✓ Multiple anticoagulation options exist, each with unique pros and cons
✓ Thrombophilias range from mild (Factor V Leiden) to severe (antithrombin deficiency)
✓ Many inherited thrombophilias don't require prophylactic anticoagulation without additional risk factors
✓ Timing of testing is crucial—avoid testing during acute events or while on anticoagulation
✓ Hormonal factors play significant roles, especially in protein S deficiency
✓ Compound heterozygotes face significantly higher risks
✓ With proper management, most people with thrombophilias live normal, healthy lives

Venous Thromboembolism - Introduction to VTE, Virchow's triad, signs, symptoms, and diagnosis

Venous Thromboembolism Management - Acute treatment approaches and anticoagulation options

Thrombophilias Overview - Introduction to hypercoagulable conditions and Factor V Leiden

Prothrombin Gene Mutation G20210A - Second most common inherited thrombophilia

Antithrombin III Deficiency - High-risk inherited thrombophilia

Protein C and S Deficiency - Natural anticoagulant deficiencies

Disclaimer: The content in this guide is for educational purposes only and should not be considered medical advice. Always consult your physician with specific questions regarding your health.

I hope you found this helpful! Click the subscribe button below to receive more content straight to your inbox!